Yorkshire tech designed to help AI in cancer diagnostics set for roll-out on global stage

A pioneering pathology technology developed by Leeds Teaching Hospitals NHS Trust is set for international deployment after the team behind it secured a new commercial agreement.

Known as TANGO, the technology is a world-first, laboratory tool developed by researchers at Leeds Teaching Hospitals’ National Pathology Imaging Cooperative (NPIC).

While many cancer diagnostic tests rely on traditional staining techniques to make cells visible under a microscope, the TANGO technology is designed to support the adoption of digital pathology and artificial intelligence (AI) in cancer diagnostics.

The team behind the tech have now secured an agreement with Epredi, the world's largest diagnostic glass slide manufacturer.

Professor David Brettle, chief scientific officer at Leeds Teaching Hospitals NHS Trust.placeholder image
Professor David Brettle, chief scientific officer at Leeds Teaching Hospitals NHS Trust.

Under the agreement, Epredia plans to develop new pathology slide products incorporating TANGO.

The firm will also seek to bring the technology to market and make it accessible to other pathology laboratories.

The companies said the move will mean that TANGO is now available for wider roll-out in the NHS and internationally, adding that it could also unlock new investment into UK health technology.

Professor David Brettle, chief scientific officer at Leeds Teaching Hospitals NHS Trust, said: “This is a proud moment for Leeds and for the NHS. TANGO was developed to offer a powerful solution in digital pathology to support clinical practice and this shows how ideas developed on the frontline in the NHS can grow into innovations with global impact.

“By partnering with Epredia, we now have an opportunity to deploy this technology across the NHS and far wider, helping laboratories to adopt AI-enabled cancer diagnostics and ultimately provide patients with quicker results."

TANGO was developed by Leeds Teaching Hospitals clinicians and researchers Professor David Brettle, Professor Darren Treanor and Dr Catriona Dunn, who identified a widespread challenge in pathology labs. In diagnostic staining, slight variations can affect how results are interpreted and limit the effectiveness of AI tools.

TANGO uses a specially designed reference slide that acts as a quality control measure during staining, helping laboratories reduce variation, ensure consistent results and supporting faster more efficient cancer diagnostics.

Antony Kildare, chair of Leeds Teaching Hospitals NHS Trust, said that the agreement marked an “exciting step forward for the Trust” adding that it “builds on Leeds’ reputation as a centre for healthtech excellence by taking home-grown innovation to the global stage”. Steven Lynum, president and CEO at Epredia, said: “We share Leeds Teaching Hospitals’ passion and ambition for driving healthtech innovations and solutions to generate real-world change.

“Digital pathology and AI have the potential to help accelerate cancer diagnostics speed and quality and ultimately improve patient care.

“By adding this powerful innovation to our world-class portfolio of precision cancer diagnostics products, we are investing in technologies that can help make that future a reality.”

Epredia said it now plans to begin integrating TANGO into new laboratory slides from late 2026.

Tracy Brabin, Mayor of West Yorkshire, said: “This is an incredible example of how our world leading hospitals, universities and businesses are working together to drive the development of life-changing technologies – improving patient care and creating high-skilled jobs for local people.”

News you can trust since 1754
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice